Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Protecting Cancer Patients Against COVID-19: New Strains, New Vaccines, One Year from Vaccine Approvals

ESMO-Webinar-Series-Protecting-Cancer-Patients-1000x250-New-Strains

It is with great pleasure that I invite you to participate in the second webinar of a new ESMO short series: Protecting Cancer Patients against COVID-19, which will focus on new variants, vaccines and therapeutics and summarise evidence available one-year post-COVID-19 vaccines approvals.

This webinar is developed with the aim to provide an overview of efficacy of COVID-19 vaccines in patients with cancer while new variants are emerging. It will also highlight novel technologies and provide insights in research progress on second generation vaccine development.

I am delighted to announce the distinguished speakers who will join me in this webinar. We will begin with a lecture on emergence of new variants of concern by covering mechanisms, impact on herd immunity and mitigation strategies. This will follow with elaboration on ongoing research in second generation of COVID-19 vaccines and novel technologies. Finally, we will evaluate the efficacy and safety of COVID-19 vaccines and therapeutics in people with cancer in the context of clinical trials, registries, or retrospective real-world data.

The programme is designed to provide an overview of the current evidence, offer expert opinion exchange, and provide some important considerations with regard to new virus variants and new vaccines one year from first vaccine approvals. I strongly encourage and invite you to register and join us all in this new ESMO activity.

Prof. John Haanen
Netherlands Cancer Institute, Amsterdam, Netherlands

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

John B. Haanen

20 min

Ongoing research in 2nd generation anti-SARS-CoV-2 vaccines and novel technologies

Danny Altmann

15 min

Evaluating the efficacy and safety of anti-SARS-CoV-2 vaccines and therapeutics in people with cancer: trials, registries or retrospective RWD?

Petros Grivas

15 min

LIVE Q&A

All

*Programme changed due to unforeseen circumstances

A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event.

Learning objectives:

  • To provide an updated overview of efficacy and safety of anti-SARS-CoV-2 vaccines in patients with cancer
  • To highlight emerging data on monitoring and enhancing vaccine-induced immunity
  • To highlight therapeutic interventions beyond vaccines for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients
  • To provide insights in research progress on second generation vaccine development

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.